Patient Leaflet Updated 09-Aug-2024 | Ranbaxy (UK) Limited a Sun Pharmaceutical Company
Solifenacin succinate 5 mg film-coated tablets
Solifenacin succinate 5 mg film-coated tablets
solifenacin succinate
1. What Solifenacin succinate is and what it is used for
2. What you need to know before you take Solifenacin succinate
3. How to take Solifenacin succinate
4. Possible side effects
5. How to store Solifenacin succinate
6. Contents of the pack and other information
The active substance of Solifenacin succinate belongs to the group of medicines called anticholinergics. These medicines are used to reduce the activity of an overactive bladder. This enables you to wait longer before having to go to the bathroom and increases the amount of urine that can be held by your bladder.
Solifenacin succinate is used to treat the symptoms of a condition called overactive bladder. These symptoms include: having a strong, sudden urge to urinate without prior warning, having to urinate frequently or wetting yourself because you could not get to the bathroom in time.
Tell your doctor if you have or have ever had any of the above mentioned conditions before treatment with Solifenacin succinate starts.
Talk to your doctor or pharmacist before taking Solifenacin succinate
Tell your doctor if you have or have ever had any of the above mentioned conditions before treatment with Solifenacin succinate starts.
Before starting Solifenacin succinate, your doctor will check whether there are other causes for your need to pass urine frequently (for example heart failure (insufficient pumping power of the heart) or kidney disease). If you have a urinary tract infection, your doctor will prescribe an antibiotic (a treatment against particular bacterial infections).
Solifenacin succinate is not to be used in children or adolescents under 18 years.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
It is especially important to tell your doctor if you are taking:
Solifenacin succinate can be taken with or without food.
You should not use Solifenacin succinate if you are pregnant unless your doctor has told you to.
Do not use Solifenacin succinate if you are breast-feeding as solifenacin may get into your breast milk.
Ask your doctor or pharmacist for advice before taking this medicine.
Solifenacin succinate may cause blurred vision and sometimes sleepiness or tiredness. If you suffer from any of these side effects, do not drive or operate machinery.
Solifenacin succinate contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
Adults
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
You should swallow the whole tablet with some liquid. It can be taken with or without food. Do not crush the tablets.
The recommended dose is 5 mg per day, unless your doctor told you to take 10 mg per day.
If you have taken too much Solifenacin succinate or if a child has accidentally taken Solifenacin succinate, contact your doctor or pharmacist immediately.
Symptoms of overdose may include: headache, dry mouth, dizziness, drowsiness and blurred vision, perceiving things that are not there (hallucinations), over- excitability, seizures (convulsions), difficulty breathing, elevated heart rate (tachycardia), accumulation of urine in the bladder (urinary retention) and dilated pupils (mydriasis).
If you forget to take a dose at the usual time, take it as soon as you remember, unless it is time to take your next dose. Never take more than one dose per day. If you are in doubt, always consult your doctor or pharmacist.
Do not take a double dose to make up for a forgotten dose.
If you stop taking Solifenacin succinate, your symptoms of overactive bladder may return or worsen. Always consult your doctor, if you are considering stopping the treatment.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop taking this medicine and contact your doctor immediately if you experience any of the following:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Very rare (may affect up to 1 in 10,000 people)
Not known (frequency cannot be estimated from the available data)
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton, bottle and blister after EXP. The expiry date refers to the last day of that month.
This medicinal product does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Solifenacin succinate 5 mg film-coated tablets are off white to light yellow colored film coated round biconvex tablets embossed with code ‘RK75’ on one side and plain on the other side. The tablets are about 7.5 mm long.
Solifenacin succinate tablets are available in PVC/PVDC blister pack and 40 ml HDPE bottle pack.
Pack sizes in blisters
30, 50, 90 or 100 tablets
Pack sizes in bottles
30, 50, 90 or 100 tablets
Not all pack sizes may be marketed.
Manufacturer:
Or
Or
This medicine is authorised in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:
Netherlands: Solifenacinesuccinaat SUN
Germany: SOLIFENACIN BASICS
Spain: Solifenacina SUN
Poland: SILAMIL
United Kingdom (Northern Ireland): Solifenacin succinate
This leaflet was last revised in May 2024.
V005
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW, UK
+44 (0) 208 848 5052